Czech/SlovakiaCzech RepublicSlovakia

Generic pushinto CEE

12.05.2006

Prague - The French pharma giant Sanofi-Aventis S.A. strengthened its generics business in Central and Eastern Europe (CEE) with a participation in the Czech generics producer Zentiva a.s. According to Sanofi-Aventis, the company has acquired a 25% share in Zentiva for a total of Euro430 million from the private equity holding Warburg Pincus as well as from several Zentiva managers and employees. The move turns Sanofi-Aventis into Zentiva's biggest shareholder. Even though there are no current plans for a further increase of the participation, Sanofi-Aventis holds options to acquire further shares from the management.
Presently, Zentiva is active in Romania, the Czech Republic and Slovakia, and is developing rapidly in Poland, Russia and the Baltic states. Last year the group's 4,200 employees generated a turnover of Euro410 million with net revenues at Euro65 million. Zentiva specialises in cardio-vascular, CNS as well as gastro-intestinal diseases.

Czech/SlovakiaCzech RepublicSlovakia

21.02.2009

Prague – At a meeting with Czech stakeholders in Prague in December, EuropaBio expressed its appreciation that the Czech Republic is one of the ‘pro-biotech’ EU member states. In January when the Czech Republic took over the...

Czech/SlovakiaCzech RepublicSlovakia

11.11.2008

Prague/Tokyo – Tokyo-based Otsuka Pharmaceutical has established its first research, development and manufacturing facility in Eastern Europe. By the end of August, the diversified company had completed the acquisition of Czech...

Czech/SlovakiaCzech RepublicSlovakia

22.08.2008

Prague – Czech scientists have appealed to the European Council not to to politicise the approval process for biotech crops. “Although the EU has the strictest rules on GM plants in the world, politicians in Brussels prefer to...

Czech/SlovakiaCzech RepublicSlovakia

16.07.2008

Brno – Czech biotechnologists and EU industry experts have worked out an action plan to improve the development of industrial biotechnology in the Czech Republic. The recommendations are based on three SWOT analyses (R&D,...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Bratisava – German Lanxess, specialist for the development, manufacture and distribution of specialty chemicals and intermediates, has opened a new sales company for Central/Eastern Europe in Bratislava. This is its 3rd...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Prague – Gate2biotech has released a report on what’s going on in biotechnology in the Czech Republic. Windows-users can download a free electronic copy of the company registry and academic landscape or order a hardcopy at:...

Czech/SlovakiaCzech RepublicSlovakia

19.03.2008

Prague – The worldwide clinical research organisation Icon plc (Dublin, Ireland) has further expanded its activities in Eastern Europe. The CRO opened offices in Prague (Czech Republic), Kiev (Ukraine), and Bucharest (Romania),...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – The Czech Republic has increased its R&D expenditures significantly in the last year. At a1.88 billion, R&D investments rose by 18% compared to 2005, the second largest increase world-wide. Those expenditures achieved...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Kourim/Basel – Lonza Biotec s.r.o. (Kourim, Czech Republic), a specialist for microbial fermentation and manufacturing services, has completed the extension of its production plant in Kourim designed for the cGMP-compliant...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – Prague Clinical Services s.r.o. will conduct the pivotal phase III trials in Europe for Gia­conda Ltd.’s (Sydney, Australia) lead product Myoconda®, an anti­biotic combination therapy for the treatment of MAP infection...

Displaying results 21 to 30 out of 70

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/2/article/generic-pushinto-cee.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.13 CHF4.68%
  • CO.DON3.15 EUR4.30%
  • BB BIOTECH146.25 EUR2.17%

FLOP

  • WILEX2.35 EUR-5.24%
  • SANTHERA89.15 CHF-3.10%
  • EVOTEC2.93 EUR-2.33%

TOP

  • SANTHERA89.15 CHF31.2%
  • CO.DON3.15 EUR26.0%
  • PAION3.01 EUR24.4%

FLOP

  • ADDEX3.13 CHF-22.3%
  • EVOTEC2.93 EUR-21.2%
  • MEDIGENE3.95 EUR-15.1%

TOP

  • SANTHERA89.15 CHF2117.7%
  • CO.DON3.15 EUR250.0%
  • PAION3.01 EUR189.4%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.67 EUR-40.6%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014


Current issue

All issues

Product of the week

Products